{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Cellgram-LC",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "To evaluate the efficacy and efficacy for 60 months after a single dose of Cellgram-LC in patients with alcoholic liver cirrhosis."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nAt the time of screening, 19 or 70 years\nPatients diagnosed with alcoholic cirrhosis by combining alcohol history, imaging and pathological examination results, and clinical symptoms at screening, and belonging to Child-Pugh grade B or C (Child-Pugh score of 7 or more)\nThose whose survival period is more than 1 year when judged by the tester\nThose who can perform hepatic artery catheterization by inserting a catheter into the hepatic artery at the judgment of the examiner\nIn the case of women of childbearing potential, a person who was confirmed negative in the pregnancy test at screening and agreed to use contraception* by the method permitted for this clinical trial during the clinical trial\nThose who can conduct clinical trials according to the clinical trial protocol\nA person who has consented in writing to voluntarily participate in this clinical trial\n\nExclusion Criteria:\n\nThose with a history of solid cancer including Hepatocellular Carcinoma (HCC) (within 5 years before screening), those who have been diagnosed with solid cancer and are currently undergoing chemotherapy or those whose hepatocellular carcinoma has been confirmed by screening tests\nPatients who underwent portal systemic shunting in the jugular vein\nPatients with alcohol consumption or hepatotoxic drugs within 6 months prior to screening\nPersons taking high-dose steroids, immunosuppressants, or antimicrobials due to severe infections for at least 1 month of screening\nThose who have major surgical operations, long-term biopsy, or significant trauma as judged by the investigator within 3 months before screening\nThose whose history of gastrointestinal bleeding is confirmed within 10 days of screening\n\nThose whose medical history or accompanying diseases following the screening time is confirmed\n\nIf you have not been diagnosed with a malignant blood disease (acute myelogenous leukemia, acute lymphocytic leukemia, non-Hodgkins lymphoma, Hodgkins lymphoma, multiple myelopathy)\nSevere aplastic anemia\nLiver transplant history\nLiver diseases of other causes besides alcoholic cirrhosis: hepatitis B and C, autoimmune liver disease (primary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis, etc.), weak liver toxicity, non-alcoholic fatty liver disease , NAFLD), Wilson's disease, iron excess, alpha-1-antitrypsin deficiency, etc.)\nExtrahepatic biliary stenosis\nActive portal vein or hepatic vein thrombosis\nHeart failure or respiratory failure\nSevere renal impairment (when the result of serum creatinine test exceeds 1.5 times the upper limit of normal)\nAcute or chronic infection requiring systemic treatment\nSevere coagulation disorder (if the tester judges it as a severe coagulation disorder or one of the following 1 to 3; 1. bleeding predisposition, 2. coagulation, 3. platelet\u226450,000/mm3 and INR\u22651.5)\nserologic test result (HIV, HAV, HBV, HCV, Syphilis infection) positive factor\nPatients unable to collect bone marrow due to bone marrow disease\nThose with a history of gentamicin hypersensitivity reaction\nPregnant or lactating women\nThose with substance abuse experience within 1 year before screening\nThose who participated in other clinical trials within one month before screening and administered (or applied) clinical trial drugs (or medical devices)\nThose who previously participated in clinical trials related to cell therapy\nPatients judged to be inappropriate to participate in this clinical trial due to complications, etc., when judged by the investigator before screening or registration"
                        ],
                        "EnrollmentCount": [
                              "200"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04689152"
                        ]
                  }
            ]
      }
}